# US 2013/0156802 A1 · Cholera Toxin Chimera and its Use as a Staph Vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156802 A1
- Document ID: US20130156802A1
- Status: Published application
- Kind: A1
- Application number: 13/328,686
- Filed: 2011-12-16
- Published: 2013-06-20
- Earliest claimed: 2011-12-16
- Assignees: Boise State University
- Inventors: Juliette Tinker
- Web page: https://patentgrep.com/patent/US20130156802A1

## CPC

- A61K 39/085: Staphylococcus
- A61K 39/107: {Vibrio}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 14/28: from Vibrionaceae (F)
- C07K 14/31: from Staphylococcus (G)
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- A61K 2039/543: {intranasal}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/575: {humoral response}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- C07K 14/245: Escherichia (G)
- C07K 14/25: Shigella (G)
- C07K 2319/00: Fusion polypeptide
- Y10S 424/823: Bacterial vaccine for bovine species, e.g. cattle
- Y10S 424/828: Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
- Y10S 424/829: Bacterial vaccine for equine species, e.g. horses
- Y10S 530/825: Bacteria
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.

## Claims

### Claim 1

A method of generating an immune response in a mammal comprising:
administering to the mammal a composition comprising:
a chimeric protein comprising at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and
an antigen comprising at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.

### Claim 2 (depends on 1)

The method of claim 1 wherein the composition is a single polypeptide.

### Claim 3 (depends on 1)

The method of claim 1 wherein the composition has at least about 80% sequence identity to SEQ ID NO: 5, 10, or 15.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is assembled from a first polypeptide and a second polypeptide that are non-covalently linked.

### Claim 5 (depends on 4)

The method of claim 4, wherein the first polypeptide has at least about 80% sequence identity to SEQ ID NO: 6, 11, or 16.

### Claim 6 (depends on 4)

The method of claim 4, wherein the second polypeptide has at least about 80% sequence identity to SEQ ID NO: 3, 9, or 14.

### Claim 7 (depends on 1)

The method of claim 1 wherein the composition is a fusion protein.

### Claim 8 (depends on 1)

The method of claim 1 wherein the antigen is selected from the group consisting of: iron-regulated surface determinant A (IsdA), iron-regulated surface determinant B (IsdB), clumping factor B (ClfB), fibronectin-binding protein (FnBP), penicillin binding protein 2a (PBP2A), serine-aspartate rich fibrinogen sialoprotein binding protein (SrdE), and any combination thereof.

### Claim 9 (depends on 1)

The method of claim 1 wherein the mammal is selected from the group consisting of: a human, a cow, a dog, a cat, a horse, and any combination thereof.

### Claim 10 (depends on 1)

The method of claim 1 wherein the administration of the chimeric protein is selected from the group consisting of: intranasal administration, oral administration, intramuscular administration, peritoneal administration, sublingual administration, transcutaneous administration, subcutaneous administration, intravaginal administration, intrarectal administration, and any combination thereof.

### Claim 11

A method of vaccinating a cow comprising:
administering to the cow, a chimeric protein comprising:
an adjuvant selected from the group consisting of: a portion of a cholera toxin, a portion of a heat-labile toxin, a portion of a shiga toxin, and any combination thereof; and
an antigen selected from the group consisting of: an antigenic material from S. aureus, an antigenic material from an S. aureus-specific polypeptide, and any combination thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the adjuvant is one of: CTA2/B, LTA2/B, or STA2/B.

### Claim 13 (depends on 12)

The method of claim 12, wherein the adjuvant further comprises at least one additional cholera toxin B subunit, heat-labile toxin B subunit, or shiga toxin B subunit.

### Claim 14 (depends on 12)

The method of claim 12, wherein the adjuvant further comprises at least one additional cholera toxin A2 subunit, heat-labile toxin A2 subunit, or shiga toxin A2 subunit.

### Claim 15 (depends on 11)

The method of claim 11 wherein the antigen is selected from the group consisting of: iron-regulated surface determinant A (IsdA), iron-regulated surface determinant B (IsdB), clumping factor B (ClfB), fibronectin-binding protein (FnBP), penicillin binding protein 2a (PBP2A), serine-aspartate rich fibrinogen sialoprotein binding protein (SrdE), and any combination thereof.

### Claim 16 (depends on 11)

The method of claim 11 wherein the administration of the chimeric protein is selected from the group consisting of: intranasal administration, oral administration, intramuscular administration, peritoneal administration, sublingual administration, transcutaneous administration, subcutaneous administration, intravaginal administration, intrarectal administration, and any combination thereof.

### Claim 17 (depends on 11)

The method of claim 11, wherein the chimeric protein is assembled from a first polypeptide and a second polypeptide that are non-covalently linked.

### Claim 18 (depends on 17)

The method of claim 17, wherein the first polypeptide has at least about 80% sequence identity to SEQ ID NO: 6, 11, or 16.

### Claim 19 (depends on 17)

The method of claim 17, wherein the second polypeptide has at least about 80% sequence identity to SEQ ID NO: 3, 9, or 14.

### Claim 20 (depends on 11)

The method of claim 11, wherein the chimeric protein has at least about 80% sequence identity to SEQ ID NO: 5, 10, or 15.
